Annual Operating Expenses
$7.07 B
+$1.45 B+25.80%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual total operating expenses is currently $7.07 billion, with the most recent change of +$1.45 billion (+25.80%) on 31 December 2023. During the last 3 years, it has risen by +$3.27 billion (+85.98%). REGN annual operating expenses is now at all-time high.REGN Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$1.99 B
+$20.50 M+1.04%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly total operating expenses is currently $1.99 billion, with the most recent change of +$20.50 million (+1.04%) on 30 September 2024. Over the past year, it has increased by +$278.60 million (+16.24%). REGN quarterly operating expenses is now at all-time high.REGN Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +25.8% | +16.2% |
| 3 y3 years | +86.0% | +73.0% |
| 5 y5 years | +222.2% | +155.7% |
REGN Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +86.0% | at high | +73.0% |
| 5 y | 5 years | at high | +222.2% | at high | +155.7% |
| alltime | all time | at high | >+9999.0% | at high | +537.3% |
Regeneron Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.99 B(+1.0%) |
| June 2024 | - | $1.97 B(+1.1%) |
| Mar 2024 | - | $1.95 B(+2.0%) |
| Dec 2023 | $7.07 B(+25.8%) | $1.91 B(+11.6%) |
| Sept 2023 | - | $1.72 B(-1.2%) |
| June 2023 | - | $1.74 B(+2.1%) |
| Mar 2023 | - | $1.70 B(+0.3%) |
| Dec 2022 | $5.62 B(+21.1%) | $1.70 B(+21.7%) |
| Sept 2022 | - | $1.39 B(+11.3%) |
| June 2022 | - | $1.25 B(-1.6%) |
| Mar 2022 | - | $1.27 B(-0.6%) |
| Dec 2021 | $4.64 B(+22.1%) | $1.28 B(+11.2%) |
| Sept 2021 | - | $1.15 B(+5.0%) |
| June 2021 | - | $1.10 B(-0.9%) |
| Mar 2021 | - | $1.11 B(+22.7%) |
| Dec 2020 | $3.80 B(+6.1%) | $902.80 M(-6.6%) |
| Sept 2020 | - | $966.90 M(-5.2%) |
| June 2020 | - | $1.02 B(+12.0%) |
| Mar 2020 | - | $910.80 M(-5.7%) |
| Dec 2019 | $3.58 B(+63.3%) | $966.10 M(+23.9%) |
| Sept 2019 | - | $779.70 M(-30.2%) |
| June 2019 | - | $1.12 B(+54.9%) |
| Mar 2019 | - | $720.50 M(-258.0%) |
| Dec 2018 | $2.19 B(-35.4%) | -$456.00 M(-149.2%) |
| Sept 2018 | - | $926.20 M(+3.6%) |
| June 2018 | - | $894.10 M(+7.8%) |
| Mar 2018 | - | $829.40 M(-11.6%) |
| Dec 2017 | $3.40 B(+5.1%) | $937.82 M(+12.1%) |
| Sept 2017 | - | $836.51 M(+2.4%) |
| June 2017 | - | $816.88 M(+1.6%) |
| Mar 2017 | - | $804.28 M(-0.1%) |
| Dec 2016 | $3.23 B(+31.3%) | $805.15 M(-1.0%) |
| Sept 2016 | - | $813.09 M(-4.6%) |
| June 2016 | - | $851.97 M(+12.1%) |
| Mar 2016 | - | $759.79 M(+0.5%) |
| Dec 2015 | $2.46 B(+37.3%) | $756.16 M(+18.9%) |
| Sept 2015 | - | $635.92 M(+12.6%) |
| June 2015 | - | $564.92 M(+12.5%) |
| Mar 2015 | - | $502.10 M(-4.7%) |
| Dec 2014 | $1.79 B(+48.4%) | $527.05 M(+9.4%) |
| Sept 2014 | - | $481.73 M(+23.1%) |
| June 2014 | - | $391.23 M(+0.2%) |
| Mar 2014 | - | $390.61 M(+6.4%) |
| Dec 2013 | $1.21 B(+44.2%) | $367.20 M(+14.2%) |
| Sept 2013 | - | $321.65 M(+23.7%) |
| June 2013 | - | $259.93 M(+0.9%) |
| Mar 2013 | - | $257.56 M(+7.9%) |
| Dec 2012 | $836.31 M(+29.3%) | $238.76 M(+16.4%) |
| Sept 2012 | - | $205.18 M(+5.2%) |
| June 2012 | - | $195.08 M(-1.1%) |
| Mar 2012 | - | $197.29 M(+19.3%) |
| Dec 2011 | $646.77 M(+16.6%) | $165.39 M(+2.8%) |
| Sept 2011 | - | $160.84 M(-4.1%) |
| June 2011 | - | $167.73 M(+9.8%) |
| Mar 2011 | - | $152.80 M(+4.8%) |
| Dec 2010 | $554.45 M(+22.8%) | $145.85 M(+5.9%) |
| Sept 2010 | - | $137.70 M(-1.1%) |
| June 2010 | - | $139.21 M(+5.7%) |
| Mar 2010 | - | $131.69 M(-3.0%) |
| Dec 2009 | $451.69 M(+39.5%) | $135.82 M(+14.8%) |
| Sept 2009 | - | $118.27 M(+11.7%) |
| June 2009 | - | $105.86 M(+15.4%) |
| Mar 2009 | - | $91.73 M(+6.4%) |
| Dec 2008 | $323.78 M(+35.2%) | $86.22 M(+1.2%) |
| Sept 2008 | - | $85.22 M(+6.2%) |
| June 2008 | - | $80.27 M(+11.0%) |
| Mar 2008 | - | $72.29 M(-5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $239.48 M(+47.0%) | $76.26 M(+25.1%) |
| Sept 2007 | - | $60.98 M(+15.5%) |
| June 2007 | - | $52.80 M(+6.8%) |
| Mar 2007 | - | $49.44 M(+13.9%) |
| Dec 2006 | $162.96 M(-340.4%) | $43.40 M(+6.3%) |
| Sept 2006 | - | $40.83 M(+0.3%) |
| June 2006 | - | $40.70 M(+7.0%) |
| Mar 2006 | - | $38.03 M(-118.6%) |
| Dec 2005 | -$67.78 M(-144.3%) | -$204.04 M(-531.0%) |
| Sept 2005 | - | $47.34 M(+1.0%) |
| June 2005 | - | $46.86 M(+11.4%) |
| Mar 2005 | - | $42.06 M(+6.1%) |
| Dec 2004 | $153.16 M(+1.6%) | $39.64 M(+7.1%) |
| Sept 2004 | - | $37.01 M(-8.7%) |
| June 2004 | - | $40.53 M(+12.7%) |
| Mar 2004 | - | $35.97 M(-4.1%) |
| Dec 2003 | $150.81 M(+9.7%) | $37.50 M(-2.0%) |
| Sept 2003 | - | $38.25 M(+2.8%) |
| June 2003 | - | $37.20 M(-1.7%) |
| Mar 2003 | - | $37.85 M(+0.1%) |
| Dec 2002 | $137.46 M(+35.9%) | $37.82 M(+1.9%) |
| Sept 2002 | - | $37.11 M(+10.2%) |
| June 2002 | - | $33.66 M(+16.6%) |
| Mar 2002 | - | $28.88 M(-12.1%) |
| Dec 2001 | $101.15 M(+46.6%) | $32.83 M(+19.4%) |
| Sept 2001 | - | $27.50 M(+25.1%) |
| June 2001 | - | $21.98 M(+16.7%) |
| Mar 2001 | - | $18.84 M(-6.7%) |
| Dec 2000 | $68.99 M(+26.1%) | $20.19 M(-27.8%) |
| Sept 2000 | - | $27.97 M(+63.0%) |
| June 2000 | - | $17.17 M(+7.8%) |
| Mar 2000 | - | $15.93 M(+27.4%) |
| Dec 1999 | $54.70 M(+19.4%) | $12.50 M(-18.8%) |
| Sept 1999 | - | $15.40 M(+17.6%) |
| June 1999 | - | $13.10 M(-9.7%) |
| Mar 1999 | - | $14.50 M(+20.8%) |
| Dec 1998 | $45.80 M(+20.5%) | $12.00 M(+0.8%) |
| Sept 1998 | - | $11.90 M(+2.6%) |
| June 1998 | - | $11.60 M(+10.5%) |
| Mar 1998 | - | $10.50 M(+12.9%) |
| Dec 1997 | $38.00 M(-5.7%) | $9.30 M(+1.1%) |
| Sept 1997 | - | $9.20 M(-6.1%) |
| June 1997 | - | $9.80 M(0.0%) |
| Mar 1997 | - | $9.80 M(-1.0%) |
| Dec 1996 | $40.30 M(+15.1%) | $9.90 M(-6.6%) |
| Sept 1996 | - | $10.60 M(+7.1%) |
| June 1996 | - | $9.90 M(0.0%) |
| Mar 1996 | - | $9.90 M(+16.5%) |
| Dec 1995 | $35.00 M(-33.2%) | $8.50 M(-1.2%) |
| Sept 1995 | - | $8.60 M(-3.4%) |
| June 1995 | - | $8.90 M(-1.1%) |
| Mar 1995 | - | $9.00 M(-29.7%) |
| Dec 1994 | $52.40 M(+6.1%) | $12.80 M(+1.6%) |
| Sept 1994 | - | $12.60 M(-7.4%) |
| June 1994 | - | $13.60 M(+1.5%) |
| Mar 1994 | - | $13.40 M(-68.5%) |
| Dec 1993 | $49.40 M(+65.8%) | $42.60 M(+1752.2%) |
| Sept 1993 | - | $2.30 M(-79.3%) |
| June 1993 | - | $11.10 M(-1.8%) |
| Mar 1993 | - | $11.30 M(+34.5%) |
| Dec 1992 | $29.80 M(+626.8%) | $8.40 M(+5.0%) |
| Sept 1992 | - | $8.00 M(+19.4%) |
| June 1992 | - | $6.70 M(0.0%) |
| Mar 1992 | - | $6.70 M(+857.1%) |
| Dec 1991 | $4.10 M(+105.0%) | $700.00 K(-65.0%) |
| Sept 1991 | - | $2.00 M(+150.0%) |
| June 1991 | - | $800.00 K |
| Dec 1990 | $2.00 M | - |
FAQ
- What is Regeneron Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual operating expenses year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly operating expenses year-on-year change?
What is Regeneron Pharmaceuticals annual total operating expenses?
The current annual operating expenses of REGN is $7.07 B
What is the all time high annual operating expenses for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total operating expenses is $7.07 B
What is Regeneron Pharmaceuticals annual operating expenses year-on-year change?
Over the past year, REGN annual total operating expenses has changed by +$1.45 B (+25.80%)
What is Regeneron Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of REGN is $1.99 B
What is the all time high quarterly operating expenses for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total operating expenses is $1.99 B
What is Regeneron Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, REGN quarterly total operating expenses has changed by +$278.60 M (+16.24%)